HROW

Harrow, Inc.

$42.93 +1.56 (+3.77%) At close · Jul 15

Market Cap

$1.67B

37,275,107

Up next

Next earnings call

Aug 12, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.7 · calm Equity put/call 0.67

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +4%

above

Price vs 50-day avg +14%

above

RSI (14) 57

neutral

MACD trend Negative

52-week position 55%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +10%

trailing

6-month return −9%

trailing

YTD return −12%

this year

Relative strength −19%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $38 › 200d $41 — 200d above 50d

Institutional flow Distributing

15 of 219 funds reported for Jun 30 · net -6.5K sh shares

Insider flow Accumulating

Net +$468.7K over 90 days · 0% sells

Short interest Falling

19.18% of float · ▼ -2.2% MoM · 7.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

219 holders — near 3-yr high, broad support

Squeeze score 74

high risk · 0–100

Fundamentals

Excellent

Revenue growth +36%

Y/Y

Gross margin 75%

contracting

EPS growth +71%

Y/Y

Free cash flow $43.0M

Balance sheet $177.1M

net debt

Quant / Vol

risk profile

Very High

Volatility 65%

annualized · 1-yr

Max drawdown −47%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 11, 2026

Second Quarter

Revenue Initiated $71M – $81M

prior qtr $44.2M midpoint +71.9% QoQ

Full-year 2026

Revenue Maintained $350M – $365M

prior FY $272.3M midpoint +31.3% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+4% Bullish

Price vs 50-day avg

+14% Bullish

RSI (14)

57 Neutral

MACD trend

Negative Bearish

52-week position

55% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $38 › 200d $41 — 200d above 50d

Institutional flow Distributing

15 of 219 funds reported for Jun 30 · net -6.5K sh shares

Insider flow Accumulating

Net +$468.7K over 90 days · 0% sells

Short interest Falling

19.18% of float · ▼ -2.2% MoM · 7.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

219 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $29 Now $43 · 55% 52-wk high $55

vs 200-day avg +4% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
TRIESENCE new accounts	195	Q1 2026	—
adjusted EBITDA non-GAAP	-$12.7M	Q1 2026 call	—

new sales professionals hired	90	Q1 2026 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HROW Harrow, Inc. this stock	$1.67B	-12.4%	+36.4%	—	19.2%
TAK Takeda Pharmaceutical Co Ltd	$53.43B	+7.3%	—	—	0.2%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$51.90B	—	—	—	0.0%
GALDY Galderma Group AG/ADR	$49.13B	-0.2%	—	—	0.0%
HLN Haleon plc	$44.52B	+0.0%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

218

% held: 61.0%
Reported: 15 of 219
Top holder: Opaleye Management Inc.

Held Float

View

Held by Funds

Fund positions

159

View

Short & Settlement

Short Interest Falling

Shares short

7.1M

Days to cover: 7.8d
Change: -158.8K sh

View

Short Volume

Short vol %

60%

As of: Jul 16, 2026

Short Total

View

Fails to Deliver

FTD shares

126

Value: $5.2K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

51.6%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Cluster buy

Net (90d)

+$468.7K

Buyers / Sellers: 4 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$272.3M

Net income (FY): $-5.1M
EPS diluted: $-0.14

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 13

View

Exempt Offerings

Offering

$10.7M

Filed: May 14, 2021

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
HROW	-4.8%	+10.3%	-8.9%	+1.1%	-12.4%
SPY	+1.3%	-0.2%	+10.1%	+1.1%	+10.7%
vs SPY	-6.0%	+10.4%	-19.0%	+0.0%	-23.1%

Key facts CIK 1360214 CUSIP 415858109 13F (30d) 15 filings 15 filers Visit website Investor relations

HROW

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance